Biotechnology News and Research

RSS

Simulations Plus to distribute quarterly cash dividend in May 2013

Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its Board of Directors has decided to distribute a cash dividend in May.

26 Apr 2013

Immudex signs agreement to provide MHC-peptide multimer and Elispot proficiency panel services

Immudex has entered into a strategic agreement with the US Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute, and the European Association for Cancer Immunotherapy (CIMT), under which Immudex will provide MHC-peptide multimer and Elispot proficiency panel services worldwide.

26 Apr 2013

Violence and Gender: New refereed journal delves into gender basis of violence

Delving into controversial and unsettling subjects such as the gender basis of violence, the new refereed journal Violence and Gender, launching in fall 2013, will explore the difficult issues that are vital to threat assessment and prevention of the epidemic of violence.

26 Apr 2013

Phase I/II data on Baxter's Lyme disease candidate vaccine presented at NFID conference

Baxter International Inc. today announced Phase I/II data evaluating the safety and immunogenicity of its investigational Lyme disease candidate vaccine during the National Foundation for Infectious Diseases 16th Annual Conference on Vaccine Research in Baltimore, Md.

From Baxter International Inc. 25 Apr 2013

Acucela begins phase 2b/3 clinical trial of emixustat hydrochloride to treat GA associated with dry AMD

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for sight threatening eye diseases, today announced that a phase 2b/3 clinical trial investigating emixustat hydrochloride in subjects with geographic atrophy associated with dry age-related macular degeneration has been initiated.

25 Apr 2013

Cultivation of legumes helps farmers add natural nitrogen to agricultural fields

The overuse of nitrogen fertilizers in agriculture can wreak havoc on waterways, health and the environment.

25 Apr 2013

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia.

24 Apr 2013

Advaita selected to participate in Michigan I-Corps program starting May 2013

Advaita, a Plymouth, MI biotechnology startup company spun out from Wayne State University, is one of 25 companies selected to participate in the new Michigan I-Corps program starting May 2013.

24 Apr 2013

FDA grants orphan-drug designation to XEN402 for treatment of pain associated with EM

Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announced today that the US Food and Drug Administration has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia.

24 Apr 2013

Individual cancer cells in blood stream are responsible for metastases in breast cancer patients

Individual cancer cells that break away from the original tumor and circulate through the blood stream are considered responsible for the development of metastases. These dreaded secondary tumors are the main cause of cancer-related deaths.

23 Apr 2013

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013.

23 Apr 2013

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Mayo Clinic and Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis.

23 Apr 2013

GeneCapture developing new device with one-hour pathogen testing capabilities

A company hatched as a partnership between The University of Alabama in Huntsville and chemical engineering professor Dr. Krishnan Chittur is in the design phase for a device that can provide physicians one-hour pathogen testing capabilities.

23 Apr 2013

Senesco completes cohort 2 in Phase 1b/2a clinical study of SNS01-T

Senesco Technologies, Inc. reported today that it has completed cohort 2 in its Phase 1b/2a clinical study of SNS01-T.

23 Apr 2013

Integral Molecular releases MPS antibody discovery platform

ntegral Molecular, Inc., a leader in membrane protein reagents and services, announces the launch of its Membrane Protein Solutions antibody discovery platform.

23 Apr 2013

University of Utah researchers develop novel technique to identify RNA cytosine methyltransferases

Researchers from Huntsman Cancer Institute at the University of Utah have developed a novel and powerful technique to identify the targets for a group of enzymes called RNA cytosine methyltransferases in human RNA.

23 Apr 2013

International team of researchers joins forces to decode genome of prehistoric fish

An enigmatic prehistoric fish has brought scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) together with researchers from all over the world to crack its genomic code.

22 Apr 2013

Study provides medical chemists with tools to design safer drugs, predict their side effects

Yellow vision, pseudo-pulmonary obstruction, involuntary body movements, respiratory paralysis. These are some of the 1,600 known side effects (SEs) produced by drugs.

22 Apr 2013

Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV-associated anal cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the first patient has been dosed in a Phase 1/2 study of ADXS-HPV in 25 patients with HPV-associated anal cancer coordinated by the Brown University Oncology Research Group (BrUOG).

22 Apr 2013

Advaxis to license its ADXS-HPV product candidate to FusionVax

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has entered into a Memorandum of Understanding (MoU) with FusionVax, Inc. ("FusionVax") setting forth the main terms under which Advaxis will, subject to the entry of a definitive agreement, exclusively license its lead clinical stage product candidate, ADXS-HPV, to FusionVax for Asia.

22 Apr 2013

Biotechnology News and Research

Simulations Plus to distribute quarterly cash dividend in May 2013

Immudex signs agreement to provide MHC-peptide multimer and Elispot proficiency panel services

Violence and Gender: New refereed journal delves into gender basis of violence

Phase I/II data on Baxter's Lyme disease candidate vaccine presented at NFID conference

Acucela begins phase 2b/3 clinical trial of emixustat hydrochloride to treat GA associated with dry AMD

Cultivation of legumes helps farmers add natural nitrogen to agricultural fields

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

Advaita selected to participate in Michigan I-Corps program starting May 2013

FDA grants orphan-drug designation to XEN402 for treatment of pain associated with EM

Individual cancer cells in blood stream are responsible for metastases in breast cancer patients

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

GeneCapture developing new device with one-hour pathogen testing capabilities

Senesco completes cohort 2 in Phase 1b/2a clinical study of SNS01-T

Integral Molecular releases MPS antibody discovery platform

University of Utah researchers develop novel technique to identify RNA cytosine methyltransferases

International team of researchers joins forces to decode genome of prehistoric fish

Study provides medical chemists with tools to design safer drugs, predict their side effects

Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV-associated anal cancer

Advaxis to license its ADXS-HPV product candidate to FusionVax

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News